NeoGenomics Snags GE Healthcare Unit Clarient

NeoGenomics has completed its acquisition of cancer diagnostic testing provider Clarient for a $80 million in cash, $110 million in preferred stock and 15 million shares of NeoGenomics common stock.

A unit of GE Healthcare, Clarient’s portfolio includes diagnostics for a variety of fields, including breast and colorectal cancer testing, as well as leukemia and lymphoma testing. As a result, GE will own about 32 percent of NeoGenomics. — Michael Cipriano